口服胰岛素折戟后缘尽：华润系14.2亿挂牌转让天麦生物股权

Core Viewpoint - After a decade of collaboration in the insulin sector, China Resources has decided to divest from Tianmai Biotech, indicating a strategic shift towards focusing on core business operations and asset optimization [1][3]. Company Summary - China Resources Pharmaceutical announced plans to publicly transfer approximately 17.87% of its stake in Tianmai Biotech, with a base price of around 1.42 billion yuan, valuing Tianmai at approximately 8 billion yuan [1][3]. - Following this transaction, China Resources' stake will decrease from 20% to 5.88%, effectively ending its position as the largest shareholder [3]. - The partnership began in 2016 during a period of growth in the domestic insulin market, with China Resources investing in Tianmai due to its technological capabilities in recombinant human insulin [5][6]. - Tianmai Biotech has faced setbacks, particularly with its oral insulin product, which failed to gain regulatory approval, impacting its competitive edge and leading to a reevaluation of its future prospects by China Resources [6][9]. Industry Summary - The insulin market in China has become increasingly competitive, with price reductions due to centralized procurement policies and the emergence of local leaders like Ganli Pharmaceutical and Tonghua Dongbao [8]. - The failure of Tianmai's oral insulin product has raised concerns about its product pipeline and growth potential, making it difficult for the company to align with China Resources' core business focus [7][9]. - The divestment reflects broader challenges faced by domestic biotech firms in maintaining capital support and commercial viability amidst high investment risks in innovative drug development [9].